---
title: "Bayesian Network Meta-Analysis of P2Y12 Inhibitors After ACS: Efficacy, Bleeding, and Uncertainty"
id: "medrxiv-2-what-additional-insights-does-a-bayesian-network-meta-analysis-provide"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-2-what-additional-insights-does-a-bayesian-network-meta-analysis-provide"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.31.26361847v1?rss=1"
published_at: "2026-09-04T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Bayesian Network Meta-Analysis of P2Y12 Inhibitors After ACS: Efficacy, Bleeding, and Uncertainty
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-2-what-additional-insights-does-a-bayesian-network-meta-analysis-provide
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.31.26361847v1?rss=1)
- **Published At:** 2026-09-04T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The authors updated a prior systematic review and performed a **Bayesian network meta-analysis** (NMA) of P2Y12 inhibitors after acute coronary syndromes (ACS), adding two trials to reach 19 randomized controlled trials (RCTs) with 60,619 patients in total. - Primary efficacy outcome was a composite major adverse cardiovascular events (**MACE**) endpoint: all-cause mortality, recurrent non-fatal myocardial infarction, or non-fatal stroke. Primary safety outcome was study-reported **major bleeding**. - The Bayesian model used a binomial complementary log-log specification with a log(time) offset and random effects; the analysis included prior and posterior predictive checks, convergence diagnostics, model comparisons, and sensitivity analyses. - The authors report probabilities for a range of practical equivalence (ROPE) defined as hazard ratio (HR) 0.90–1.11 to quantify clinically meaningful equivalence versus benefit or harm. - For MACE, prasugrel versus clopidogrel had an estimated HR 0.87 (95% credible interval [CrI] 0.76–1.03) and a 70% posterior probability of clinical efficacy benefit (HR 1.1). Prasugrel versus clopidogrel had HR 1.10 (95% CrI 0.88–1.26) with a 51% probability of meaningful bleeding harm. - The Bayesian framework highlighted clinically important uncertainties and identified probable regions of equivalence among P2Y12 inhibitors that the prior frequentist NMA— which concluded prasugrel provided an optimal efficacy-safety balance—may have underappreciated. - The authors report transparent statistical workflow details and make data and code available online at the provided GitHub repository. - Competing interests: none declared. Ethical statements: only previously published data used; trial registration and reporting guidelines followed as indicated in the source.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=C6I0AGsJsMCXapE7s.FKLW_9KRy894lEmb.hM8_Jih8-1788566858.6027672-1.2.1.1-7C1LVujIQ82TqaK2NEZ7V1l3dhYcwJlx1O6.gpoQrbOcAkZSzqV_e4oRFdPeK5mQ) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.31.26361847v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # What Additional Insights Does a Bayesian Network Meta-Analysis Provide? Revisiting P2Y12 Inhibitors After Acute Coronary Syndromes Stephen Kutcher, Nandini Dendukuri, Sonny Dandona, [ View ORCID Profile](http://orcid.org/0000-0001-8049-6875)James Brophy doi: https://doi.org/10.64898/2026.08.31.26361847 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Stephen Kutcher 1 Children's Hospital Eastern Ontario; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Stephen%2BKutcher%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kutcher%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AStephen%2BKutcher%2B) Nandini Dendukuri 2 McGill University Health Centre; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nandini%2BDendukuri%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Dendukuri%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANandini%2BDendukuri%2B) Sonny Dandona 3 McGill UniversityHealth Centre * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sonny%2BDandona%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Dandona%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASonny%2BDandona%2B) James Brophy 2 McGill University Health Centre; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=James%2BBrophy%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Brophy%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJames%2BBrophy%2B) * [ORCID record for James Brophy](http://orcid.org/0000-0001-8049-6875 "Open in new tab") * For correspondence: james.brophy@mcgill.ca * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.31.26361847v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1292952/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.31.26361847v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1292952/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.31.26361847v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1292952/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.31.26361847v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1292952/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.31.26361847v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1292952/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: The optimal P2Y12 inhibitor after percutaneous coronary intervention (PCI) remains debated. A recent frequentist network meta-analysis (NMA) concluded prasugrel provided optimal efficacy-safety balance. We update our previous Bayesian NMA with recent trials and contrast our findings with the frequentist NMA. Methods: We extended our 2023 systematic review by adding two trials published after our search cutoff. The primary efficacy endpoint was a composite of all-cause mortality, a recurrent non-fatal myocardial infarction, or non-fatal stroke (MACE). The primary safety endpoint was study-reported major bleeding events. Bayesian network meta-analysis with a primary binomial complementary log-log model with log(time) offset and random effects was performed. A statistical workflow with prior and posterior predictive checks, convergence diagnostics, model comparisons, sensitivity analyses and probabilities for a range of practical equivalence (ROPE: HR 0.90-1.11) are also reported. Results: 19 RCTs (n = 60,619) were identified. For MACE, prasugrel's probability of a clinical efficacy benefit (hazard ratio (HR) 1.1) versus clopidogrel. Conclusions: Despite 19 RCTs and approximately 60,000 patients, the Bayesian framework revealed clinically important uncertainties and identified probable regions of equivalence among the different P2Y12 inhibitors that were under appreciated with the previous frequentist publication. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Uses only previously published data I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced are available online at https://github.com/brophyj/Bayesian-NMA Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.31.26361847v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.09.01.26361953v1 "Applying Human-Centered Design and Iterative Programming to Identify and Reach Zero-Dose and Under-Immunized Children in Kenya: Lessons from the Zero-Dose Learning Agenda")[Next ](https://www.medrxiv.org/content/10.64898/2026.09.01.26360413v1 "Systematic Modality Ablation of Multimodal Machine Learning for Predicting 24-Month Progression from Mild Cognitive Impairment to Alzheimer's Disease") Posted September 04, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.31.26361847v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/04/2026.08.31.26361847.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.31.26361847v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/04/2026.08.31.26361847.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) What Additional Insights Does a Bayesian Network Meta-Analysis Provide? Revisiting P2Y12 Inhibitors After Acute Coronary Syndromes Stephen Kutcher, Nandini Dendukuri, Sonny Dandona, James Brophy medRxiv 2026.08.31.26361847; doi: https://doi.org/10.64898/2026.08.31.26361847 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.31.26361847v1%26text%3DWhat%2520Additional%2520Insights%2520Does%2520a%2520Bayesian%2520Network%2520Meta-Analysis%2520Provide%253F%2520Revisiting%2520P2Y12%2520Inhibitors%2520After%2520Acute%2520Coronary%2520Syndromes "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.31.26361847v1%26t%3DWhat%2520Additional%2520Insights%2520Does%2520a%2520Bayesian%2520Network%2520Meta-Analysis%2520Provide%253F%2520Revisiting%2520P2Y12%2520Inhibitors%2520After%2520Acute%2520Coronary%2520Syndromes "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.31.26361847v1%26title%3DWhat%2520Additional%2520Insights%2520Does%2520a%2520Bayesian%2520Network%2520Meta-Analysis%2520Provide%253F%2520Revisiting%2520P2Y12%2520Inhibitors%2520After%2520Acute%2520Coronary%2520Syndromes%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.31.26361847v1%26title%3DWhat%2520Additional%2520Insights%2520Does%2520a%2520Bayesian%2520Network%2520Meta-Analysis%2520Provide%253F%2520Revisiting%2520P2Y12%2520Inhibitors%2520After%2520Acute%2520Coronary%2520Syndromes "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.31.26361847v1&count=horizontal&via=&text=What%20Additional%20Insights%20Does%20a%20Bayesian%20Network%20Meta-Analysis%20Provide%3F%20Revisiting%20P2Y12%20Inhibitors%20After%20Acute%20Coronary%20Syndromes&counturl=www.medrxiv.org/content/10.64898/2026.08.31.26361847v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (615) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (896) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (327) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4777) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (476) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (410) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (645) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1617) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15853) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1196) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6996) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (727) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1059) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4999) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1428) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1742) * [Hematology](https://www.medrxiv.org/collection/hematology) (583) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1338) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16251) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1163) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (665) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (151) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (721) * [Neurology](https://www.medrxiv.org/collection/neurology) (7208) * [Nursing](https://www.medrxiv.org/collection/nursing) (365) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1074) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1233) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1002) * [Oncology](https://www.medrxiv.org/collection/oncology) (3581) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1039) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (394) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (448) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (466) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (139) * [Pathology](https://www.medrxiv.org/collection/pathology) (704) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1782) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (733) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (759) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5846) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9705) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2392) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1436) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1245) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (635) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (769) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (577) * [Surgery](https://www.medrxiv.org/collection/surgery) (769) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (107) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (303) * [Urology](https://www.medrxiv.org/collection/urology) (287) Evaluation/discussion of this paper x Comments 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions and read our [Comment Policy](https://connect.medrxiv.org/news/2022/03/21/commenting_on_preprints) before commenting. The content of a comment is not endorsed by medRxiv. Share this comments tab (click to copy link)Copied! TRiP medRxiv partners with journals and review services to enable posting of peer reviews and editorial decisions related to preprints they are evaluating. Reviews are posted with the consent of the authors. Community Reviews medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors. Automated Evaluations Certain services provide automated analysis of preprints. Analyses invited by the authors are displayed at the top of this tab. Those done independently of authors are shown underneath . None of these analyses is endorsed by medRxiv. Blog/Media Links medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors. Video medRxiv partners with conferences and institutions to display recordings of talks and seminars related to preprints. These are posted with the consent of the authors. Powered by [![Hypothes.is logo](https://connect.biorxiv.org/eval/hypothesis.png)](https://web.hypothes.is/) Powered by [![Altmetric logo](https://connect.biorxiv.org/eval/altmetric.png)](https://www.altmetric.com/) ## Follow this preprint X You can now receive automatic notifications when a preprint is revised, withdrawn, commented on, peer reviewed, or published in a journal. Select the events you would like to follow below and click "Submit". To see all of the preprints you are currently following, please go to the [medRxiv Alerts Page](https://medrxiv.org/alerts). Sign In to Follow this Preprint Email * Email this Articleclose Thank you for your interest in spreading the word about medRxiv. NOTE: Your em
## Related Clinical Research

- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)
- [2026 ACC/AHA Dyslipidemia Guideline: Key implications for cholesterol and cardiovascular risk](https://medichelpline.com/clinical-feed/medical-news-today-0-is-your-cholesterol-too-high-per-the-new-acc-aha-guideline-5-things-to-know.md)
- [Intensive blood pressure control linked to 15% lower 7-year dementia risk](https://medichelpline.com/clinical-feed/medical-news-today-0-intensive-blood-pressure-control-cuts-7-year-dementia-risk-by-15-study-finds.md)
- [Stepwise DAPT de-escalation vs standard DAPT after drug-coated balloon angioplasty in multivessel](https://medichelpline.com/clinical-feed/medrxiv-15-impact-of-stepwise-dual-antiplatelet-therapy-de-escalation-in-patients-with.md)
- [Genistein modifies the association between EASIX and estimated 10-year ASCVD risk](https://medichelpline.com/clinical-feed/plos-one-13-interaction-between-genistein-and-the-endothelial-activation-and-stress-index.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.